Rosetta test gets U.S. patent

Shares of Rosetta Genomics (ROSG) are up 7% premarket after the USPTO awards a patent covering the method of use of a core element of its microRNA technology in the identification of the tumor of origin in cancer of unknown or uncertain primary and metastatic cancer.

Patent No. 13,167,489 is entitled "Gene Expression Signature for Classification of Tissue of Origin of Tumor Samples." It covers the invention of methods to determine an expression profile with a primer sequence and the comparison of the expression profile that quantitates 48 microRNAs and assigns one of 25 tumor diagnoses to identify the tumor of origin.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs